Second United States Patent Granted for Small Pharma’s Psychedelics Portfolio
Brings total to twelve granted patents across the Company’s full portfolio LONDON, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Small Pharma...
Pharmaceutical
Abeona Therapeutics Announces Database Lock for Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)
NEW YORK and CLEVELAND, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the database lock...
Matinas BioPharma Announces Infectious Diseases Society of America (IDSA) has Selected the EnACT Phase 2 Trial Abstract of MAT2203 as its Outstanding Abstract and IDSA Awardee For IDWeek 2022
BEDMINSTER, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused...
Tonix Pharmaceuticals to Present at the 2022 ThinkEquity Conference
CHATHAM, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today...
Kamada Awarded $22 Million Extension of Canadian Supply Tender
Awarded Extension to Existing Supply Tender which relates to Portfolio of Four Specialty IgG Products Acquired in 2021Supply Extension Secures...
VIB and Surface Oncology Announce Publication in Cell Reports Revealing IL-27 Structure and the Mechanism of Action for SRF388
– Study reveals the structural basis of receptor activation and signaling by IL-27 cytokine –– Study elucidates how SRF388 binds to...
Amryt to Report Q3 2022 Results on November 3, 2022
Amryt to Report Q3 2022 Results on November 3, 2022 DUBLIN, Ireland, and Boston MA, October 19, 2022, Amryt (Nasdaq:...
IsoPlexis to Report Third Quarter 2022 Financial Results on November 10, 2022
BRANFORD, Conn., Oct. 19, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), a company empowering labs to leverage the cells...
Plus Therapeutics Presents Preliminary Safety and Feasibility Data from ReSPECT-LM Clinical Trial at the European Association of Nuclear Medicine Congress
ReSPECT-LM Phase 1 clinical trial selected as TOP Trials Oral Presentation Treatment was well tolerated without dose limiting toxicities and...
Tiziana Life Sciences Ltd Invites You to Join Us at The ThinkEquity Conference
NEW YORK, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (NASDAQ: TLSA), a biotechnology company developing breakthrough immunomodulation therapies...
Advaxis and Ayala Pharmaceuticals Enter into Merger Agreement
Merger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated in ongoing Phase...
Ayala Pharmaceuticals and Advaxis Enter into Merger Agreement
Merger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated in ongoing Phase...
Alvotech and JAMP Pharma Expand Exclusive Partnership Adding Two Biosimilar Candidates for Canadian Market, Bringing New Options for Patients in Specialty Care
Expanded partnership covers biosimilar candidates in immunology and oncologyREYKJAVIK, Iceland and BOUCHERVILLE, Quebec, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Alvotech...
Alvotech and JAMP Pharma Expand Exclusive Partnership Adding Two Biosimilar Candidates for Canadian Market, Bringing New Options for Patients in Specialty Care
Expanded partnership covers biosimilar candidates in immunology and oncologyAlvotech (NASDAQ: ALVO), a global biotech company specializing in the development and...
Nicox Provides Third Quarter 2022 Financial and Business Highlights
Press Release Nicox Provides Third Quarter 2022 Financial and Business HighlightsTopline results of the NCX 470 Mont Blanc Phase 3...
H1 Unveils New Brand on the Heels of Significant Financial, Customer and Product Capabilities Growth
With a refined mission to connect the world with the right doctors, new acquisition and enhanced global data solutions, H1...
Eterna Therapeutics to Present at iPSC-Derived Immunotherapies Congress
SAN DIEGO, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a biopharmaceutical company...
Salarius Pharmaceuticals Announces Pause in New Patient Enrollment in its Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma and FET-Rearranged Sarcomas
HOUSTON, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and...
Quoin Pharmaceuticals Announces Plans to Initiate a Second Clinical Trial in Netherton Syndrome Patients
A Multicenter Open Label Study of QRX003 Topical Lotion in Netherton Syndrome Patients Who Are Currently Receiving Systemic Biologic Therapy.ASHBURN,...
VectivBio Announces Closing of $125 Million Underwritten Offering of Ordinary Shares
BASEL, Switzerland, Oct. 18, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel...